KRAS Wild-type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential.
Hiroyuki KatoHaley EllisNabeel El-BardeesyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In a landscape dominated by pivotal KRAS mutations, there has been limited exploration of KRAS-wild-type pancreatic cancer. A recent study highlights other mitogen-activated kinase pathway alterations as alternative drivers in these tumors, which holds the key to unlocking a realm of targeted therapies for patients with this under-studied cancer subtype.